HealthQuill Articles by: HealthQuill
Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of 2026, according to a company statement.
Drugs Pharma

AstraZeneca to invest $570 million in Canada to boost innovation, clinical delivery

HQ Team January 26, 2025: Pharmaceutical giant AstraZeneca has announced plans to invest US$570 million in Canada over the next decade, positioning the

Read More
Scientists have converted cancer cells to healthy ones to treat a devastating pediatric cancer through a method called differentiation therapy.
Health Medical Research

SMC proteins can reverse direction; study redefines DNA dynamics

HQ Team January 26, 2025: Scientists from Delft University of Technology, Vienna Biocenter, and Lausanne have discovered that Structural Maintenance of Chromosomes (SMC)

Read More
Kisspeptin hormone could treat hypoactive sexual desire disorder when a person has an extremely low sex drive that causes distress, scientists from the Imperial College London and Imperial College Healthcare NHS Trust found.
Health Medical

Guillain Barre Syndrome outbreak in Pune causes one death, 73 affected

HQ Team January 26, 2025: Over 73 people are down with Guillain Barre Syndrome (GBS), a rare nerve disorder, in Pune city in

Read More
Covid-19
Health Medical Research

New model improves epidemic predictions by leveraging Friendship Paradox

HQ Team January 24, 2025: A recent study led by Empa researchers has developed a new mathematical model that improves predictions of how

Read More
More than 35,000 sexual safety incidents, ranging from abusive remarks to rape, have been allegedly perpetrated by staff, patients, or visitors at the National Health Service of the UK for five years ending 2022, a probe by The Guardian and British Medical Journal found.
Health Medical Research

Largest genetic study of bipolar disorder identifies 298 risk-associated genome regions

HQ Team January 24, 2025: A comprehensive genome-wide association study (GWAS) has found 298 regions containing DNA variations for increased risk of bipolar

Read More
Hyundai ADM Bio, a subsidiary of South Korea’s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous chemotherapy.
Health Medical Pharma

South Korea’s Hyundai ADM unveils oral chemotherapy drug

Hyundai ADM Bio, a subsidiary of South Korea’s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous

Read More
Climate Research

Panna Reserve’s conservation triumph in reviving India’s tigers

HQ Team January 22, 2025: The Panna Tiger Reserve in Central India has revived its tiger population from the brink of extinction to

Read More
China’s YolTech Therapeutics, a biotechnology startup, has started its clinical trial of an investigational therapy for treating transfusion-dependent beta-thalassemia (TDT), a severe genetic blood disorder.
Drugs Health Medical

China’s YolTech starts gene editing trial for treating a blood disorder 

China’s YolTech Therapeutics, a biotechnology startup, has started its clinical trial of an investigational therapy for treating transfusion-dependent beta-thalassemia (TDT), a severe genetic

Read More
The US drug regulator has issued its most prominent warning on the use of certain drugs to treat multiple sclerosis, saying it may cause hospitalisation and death due to a “rare but serious” allergic reaction.
Drugs Health Medical Pharma

US drug regulator issues warning on certain multiple sclerosis drugs

The US drug regulator has issued its most prominent warning on the use of certain drugs to treat multiple sclerosis, saying it may

Read More
US adults with attention deficit hyperactivity disorder (ADHD) rose from 10.6% to 15.2% between 2020 and 2023, and Covid-19 pandemic may be a major factor, according to a study published in Psychiatric Research and Clinical Practice.
Health Medical Research

ADHD in US adults rises to 15.2% between 2020 and 2023: Research

US adults with attention deficit hyperactivity disorder (ADHD) rose from 10.6% to 15.2% between 2020 and 2023, and Covid-19 pandemic may be a

Read More